Skip to main content

Advertisement

SpringerLink
Log in

Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C

  • Original Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

Ribavirin (RBV)-induced anemia is one of the major causes of dose reduction and discontinuation of therapy for chronic hepatitis C (CHC) patients. We investigated the role of inosine triphosphate pyrophosphatase (ITPA) single nucleotide polymorphism (SNP) (rs1127354) in predicting RBV-induced anemia and thrombocytopenia among Egyptian patients with CHC genotype 4 infection.

Methods

One hundred and twenty Egyptian patients with CHC genotype 4 who had received standard of care combination therapy were enrolled in this study. Single nucleotide polymorphism at ITPA (rs1127354) was genotyped by real-time detection polymerase chain reaction.

Results

Hb levels between CC and non-CC groups were significantly different at weeks 4, 8, and 12. Hemoglobin decline was significantly higher among CC patient than non-CC patients at week 4 and week 8 of treatment. The RBV dose reduction was higher in CC than non-CC group. Platelet decline was significantly lower in CC patients than non-CC patients at baseline, 4, 12 weeks only.

Conclusion

Rs1127354 ITPA polymorphism was associated with RBV-induced anemia and thrombocytopenia in Egyptian patients with hepatitis C virus genotype 4 infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21:639–44.

    Article  CAS  PubMed  Google Scholar 

  2. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44 Suppl 1:S19–24.

  3. Santantonio T, Sinisi E, Guastadisegni A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003;35:104–13.

    Article  CAS  PubMed  Google Scholar 

  4. Wiese M, Grungreiff K, Guthoff W, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study. J Hepatol. 2005;43:590–8.

    Article  PubMed  Google Scholar 

  5. Mostafa A, Taylor SM, el-Daly M, et al. Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. Liver Int. 2010;30:560–6.

    Article  PubMed  Google Scholar 

  6. Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.

    Article  CAS  PubMed  Google Scholar 

  9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2ª plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.

    Article  CAS  PubMed  Google Scholar 

  10. Furusyo N, Katoh M, Tanabe Y, et al. Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World J Gastroenterol. 2006;12:784–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Krishnan SM, Dixit NM. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol. 2011;7:e1001072.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcome of therapy—a genome-wide study of Japanese HCV patients. Gastroenterology. 2010;139:1190–7.

    Article  CAS  PubMed  Google Scholar 

  13. Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis. 2006;38:363–73.

    Article  CAS  PubMed  Google Scholar 

  14. Hezode C, Forestier N, Dusheiko G, PROVE2 Study Team, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–50.

    Article  CAS  PubMed  Google Scholar 

  15. McHutchison JG, Everson GT, Gordon SC, PROVE1 Study Team, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.

    Article  CAS  PubMed  Google Scholar 

  16. Suzuki F, Akuta N, Suzuki Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res. 2009;39:1056–63.

    Article  CAS  PubMed  Google Scholar 

  17. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Populationpharmacokinetic and pharmacodynamic analysis of ribavirinin patients with chronic hepatitis C. Ther Drug Monit. 2000;22:555–65.

    Article  CAS  PubMed  Google Scholar 

  18. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis. 2004;43:140–6.

    Article  CAS  PubMed  Google Scholar 

  19. Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L. Evidence that plasma concentration rather than dose per kilogram bodyweight predicts ribavirin-induced anaemia. J Viral Hepat. 2004;11:84–7.

    Article  CAS  PubMed  Google Scholar 

  20. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004;39:668–73.

    Article  CAS  PubMed  Google Scholar 

  21. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing toribavirin-induced anemia. J Gastroenterol Hepatol. 2004;19:1312–7.

    Article  CAS  PubMed  Google Scholar 

  22. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predictingsustained virological response and anaemia in chronic hepatitisC patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62:699–709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008;103:1981–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464:405–8.

    Article  CAS  PubMed  Google Scholar 

  25. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decreasethe need for ribavirin dose reduction. Gastroenterology. 2010;139:1181–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects againstanemia induced by pegylated interferon-α and ribavirintherapy for Japanese patients with chronic hepatitis C. Hepatol Res. 2010;40:1063–71.

    Article  CAS  PubMed  Google Scholar 

  27. Doehring A, Hofmann WP, Schlecker C, et al. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenet Genomics. 2011;21:289–96.

    Article  CAS  PubMed  Google Scholar 

  28. Hiramatsu N, Kurosaki M, Sakamoto N, et al. Pretreatment prediction of anemiaprogression by pegylated interferon alpha-2b plus ribavirincombination therapy in chronic hepatitis C infection: decision-tree analysis. J Gastroenterol. 2011;46:1111–9.

    Article  CAS  PubMed  Google Scholar 

  29. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A. The ITPA c.94C& gt; A and g.IVS2+21A& gt; C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta. 2007;1772:96–102.

    Article  CAS  PubMed  Google Scholar 

  30. Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000–7.

    Article  CAS  PubMed  Google Scholar 

  31. Wazny LD, Ariano RE. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy. 2000;20:292–307.

    Article  CAS  PubMed  Google Scholar 

  32. Sakamoto N, Wu GY. Prospects for future therapy of hepatitis C virus infection. Future Virol. 2009;4:453–62.

    Article  Google Scholar 

  33. Conjeevaram HS, Fried MW, Jeffers LJ, Virahep-C Study Group, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470–7.

    Article  CAS  PubMed  Google Scholar 

  34. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics. 2007;8:1221–8.

    Article  CAS  PubMed  Google Scholar 

  35. Stepchenkova EI, Tarakhovskaya ER, Spitler K, et al. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol. 2009;392:602–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31:997–1004.

    Article  PubMed  Google Scholar 

  37. Ahmed WH, Furusyo N, Zaky S, et al. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World J Gastroenterol. 2013;19:1387–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Marsh S, King CR, Ahluwalia R, McLeod HL. Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet. 2004;49:579–81.

    Article  CAS  PubMed  Google Scholar 

  39. Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet. 2002;47:620–2.

    Article  CAS  PubMed  Google Scholar 

  40. Tsubota A, Shimada N, Abe H, et al. Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. World J Gastroenterol. 2012;18:5879–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Domingo P, Guardiola JM, Salazar J, et al. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother. 2012;56:2987–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Azakami T, Hayes CN, Sezaki H, et al. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011;83:1048–57.

    Article  CAS  PubMed  Google Scholar 

  43. Tanaka Y, Kurosaki M, Nishida N, et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet. 2011;20:3507–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endemic and Infectious Diseases, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

    Nader Nemr

  2. Department of Microbiology and Immunology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

    Rania Kishk

  3. Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

    Mohamed Mandour

Authors
  1. Nader Nemr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rania Kishk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Mandour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rania Kishk.

Ethics declarations

Conflicts of interest

NN, RK, and MM do not have any conflicts to disclose.

Ethics statement

All the procedures performed in this study were in accordance with the ethical standards of the institutional research ethics committee and with the 1964 Helsinki Declaration and its later amendments.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nemr, N., Kishk, R. & Mandour, M. Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. Indian J Gastroenterol 35, 7–13 (2016). https://doi.org/10.1007/s12664-016-0618-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-016-0618-3

Keywords

Search

Navigation